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The neuropepride alpha-melanocyte stimulating hormone 
(c>-MSH) can act as an antagonist to interleukin 1 (IL-l ) 
bioactivities such as inhibition of fever production, thymo-
cyte prol iferation, and inhibition of release of acute phase 
inflammatory molecules from the liver. In this report we 
have found that epicutaneous application of Q'-MSH sup-
presses boch the sensitization and elicitation limbs of the 
cutaneous immune response (CIR) to potent contact sensi-
tizers like dini trofluorobenzene (DNFB) or oxazalone (OX) 
in mice. Further, the loss of cOntact hypersensitivity due to 
applications of c>-MSH could be reconstituted by either in-
tradermal or intravenous injections of epidennal thymocyte 
activating factor (ETAF)/interleukin-l. Topical application 
A Ipha-mclanocyte stimulating hormone (a-MSH) is a 13 amino acid peptide. one of the several proopiome-lanocorrin-derived molecules synthesized in the pirui-tary gland and, named originally for its ability to stim-ulate skin pigmentation in amphibians [1]. It is the 
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Abbreviations: 
ACTH: adenocorticotropic hormone 
CHS: contact h}'~rsensitivity 
C IR: cutaneous immune response 
DLN: draining lymph node 
DNFB: 2.4-dinitro- l -f1 uorobenzc:ne 
ELR: epidennal lymphocyte experiments 
ET A.F: epidermal thymocyte :activating factor 
IL-l : inte.rleukin t 
LC: Langerha.ns cells 
a-MSH: alph::a-melanocyte stimulating hormone 
OX: 4-ethoxymethylene-2-phrnyloxazol-5-one (oxazalone) 
PBS: phosphate-bulfcred saline 
PMN: polymorphonuclear 
POMC: proopiomelanocortin 
RBC: red blood cells 
Thyl+ DEC: Thy-l positi ve dendritic epidermal cdl 
T ,,: T helper cell s 
T.: T suppressor cells 
of a -MSH did nor cause an aheration in 13+ dendritic cells 
(i.e .• Langerhans cells) but did produce a significant reduc-
tion in the expression of Thy1.2 marker on the Thyl + 
dendritic epidetmal cells (Thy t+DEC). It has no effects on 
the phenotypic expression of asialo GM-l on these same 
ceUs. These observations suggest that c>-MSH, a peptide clas-
sically isolated from the pituitary but found in many other 
tissues and cells of the body. may represenc an additional 
biologic modifier than can modulate suppression of the con-
tact hypersensitivity responses to various haprens. However. 
the mechanisms by which c>-MSH or potentially other pep-
tides found in the skin produce these suppressive effects have 
not been elucidated. J In vest Dermato/ 93:511 -517, 1989 
classic mC'lanotropic hormone. More recently. a -MSH has been 
shown to have other functions, i.e., modulation of immune inflam-
matory processes. Although a-MSH was initi.aJly isolated from the 
pars intermedia and is considered a ncuropeptide. it has been isolated 
in a variety of other tissues and organs including tht" placC'.n ta [2.3}. 
Several investigators have documented that the pyrogenic prop-
cnics of in terleukin-I (IL- I) can be abolished by minute quantities 
of Q-MSH 14-6J. a-MSH is the most potent an tipyrogenic sub-
stance known. In addi tion to its anti pyrogenic effect, a -MSH blocks 
IL-1 induction of IL-2 receptor expression (7]. polymorphonuclear 
(PMN) chemotaxis [8) . and hepatic induction of acute phase reac-
rants including C reactive prorein and se rum amyloid P [6.9]. How-
eve.r, in other srudies a -MSH had no inh.ibi tory effect in al tering 
lL- 1-induced prostaglandin release or thymocyte stimulation with 
mitogen 16]. Other studies have demonsrrated that precursors to 
a-MSH (i.e., P-LPH and ACTH) can be found in extrapituitary 
cells. specifically thymocytes and splenocytcs. The exact role of 
Q-MSH and its precursor molecule in the moduhtion of tht" im-
mune system is still poorly defined. 
The epidermis is a source of IL-1 and/or ETAF (epidermal thy-
mocyte activating factor). Recently it has been suggested that IL-6 
may be part of rh e: ETAF complex PO). The epidermis contains 
mRNA coding for IL-ta and CL- IP. hur also a ullique mRNA wi th 
IL-l activiry referred to as K-IL..I . ETAF/ IL-I can be isolated from 
the stratum corneum and is secreted by keratinocytes III - 131. MeI-
anocytes and Langerhans cells can also secrete lL-1 [t 4, 15). 
Whether ET AF from keratinocytes and IL-t from mela.nocyces and 
Langerhans cells are identical or similar is not known. Langerha.ns 
cells and keratinocytcs play an important role in both the sensitiza-
tion and elici tation limbs of the cutaneous immune srstem follow-
ing epicutaneous application of a variety of haptens 16- 18]. 
The current investigations were carried out to determine whether 
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tOpical arMSH could abrogate functional sensitization and elicita-
tion of the cutaneous immune response to specific haptens. If so. we 
wished to determine whether exogenous administration of murine 
ETA~/ IL- l could reconstitute loss of contact hypersensitivity re-
spooslveness. 
MATERJALS AND .METHODS 
Animals Five to seven-wk-old male C57BL) 6 (H-2") mice wert;-
purchased from the Charles Rivers Laboratory, W ilmingron, MA, 
and were housed in the AAALAC approved Universiry anima,1 facil-
ities. four per cage with &ee access to water and Purina mouse chow. 
Animals were maintained on a 12-h light: dark photoperiod. All 
experiments were performed rwice and produced similar results. 
Ident i fi catio n ofla+ and Thyl+ D en d r itic Epidermal Cells 
Ia and Thyl staining of epidermal cells was performed as described 
[19,20j. Briefly. cars were surgically excised from ether vapor killed 
mice. Thf' earS were mechanicaHy splir into dorsal and ventral 
halves. Dorsal tissue was immersed in 0.020 M Na EDTA for 2 hat 
37 °C. After th~ incubation period, the epidermis was separated a5 an 
intact shec t. Staining of la+ bearing epidermal cells was p(:rformed 
by using a monoclonal anti-laP (Accorate Chemical Compan y. 
Westbury. NY) amibody diluted 1: 100 in phosphate-buffered sa-
line (PBS). This antiserum can cross react with all standard haplo-
types. The anribody was produced by growth of an hybridoma 
SP2j O myeloma cells fused witb Ralb/ e spleen cell s. The immuno-
globulin was isolated from ascinc tumors in PBS. Epidermal sheets 
were fix ed in acetone before staining with the primary antibody and 
extensively washed in PBS before indirect immunoperoxidase 
staining. A Vecta-stain ABC immu noperoxidase staining kit (Vec-
tor Laborarories. Burlingame. CA) was used foJlowing incubation 
of the primary monoclonal amibody ar 37°C for 1 h.lmmunoper-
ox.idase substrare was 3-ammo-9 ethyl carbazolf' (Sigma Chemical 
Co., St. Louis, MO) . lncuba cion for 10 min at 37 D C with the sec-
ondary reagems was followed by severaJ washes in PBS and final 
mounring in glycerol: PBS. 
Th yl + DEC were identified using double- labeling indirect im-
munofluorescence. Epidermal sbee ts were fixed in acecone followed 
by rehydration by PBS. Sheets were simultaneously labeled wirh 
mouse anti -Thy l _2 (Accurate Chemical Company. Westbury, NY) 
diluted 1; 100 or rabbit anti-asialo GM-l diluted 1 :20 (Wako 
Chemical Compan)' . Dallas. TX) for 16 11 at 4 °C. The tissue speci-
mens were washed three times ill PBS for 60 min and incubated for 
an additional 60 min at 3rC wirh either goat anrimouse rhodamine 
diluted 1: 20 or goat anti-rabbir fluorescein (FlTC) 1 : 20 in PBS_ 
Tissues were then washed extensively in PBS and mounted as de-
llcribcd [18.29). Control experiments-included epidermal sheets in 
wh ich the primary an tibodies were excluded and only secondary 
reagents were added to examine for cross-reactivity with antibody 
conjugated to rhodamine or fluorescein. 
Tht number of la+ Langerhans cells or Thy1 + dendriti c epider-
mal cd ls per square millimerer in four standardized peripheral areas 
of each epidermal sheer was determined. AI least four animals wr:.re 
studied in each group. The reported Ia+ Langerhans cel l and 
Thy 1.2+ dendritic epidermal cell demit)· for each sheet represents 
the mean of at least 16 COunts (± SE). 
T op ica l a·M SH Ad m inistration Mice were rreared on days 1 -
S by topica l application of 50 pi of to-~ M O'-MSH (Sigma C hemi-
cal C?l11pany, ~ t. Louis. MO). diluted i~ propylene glyco1. Pilor 
experlmellts usmg concentranons rangmg from 10- 5 _ 10-8 M 
a-MSH were performed. cr-MSH at 10- 5 M applied topically was 
shown to be rhe mOSt optimal concentration and therefore was used 
duoughout the se ries of experiments. M.iee ·were treated wirb 
a -MSH applied either to the dorsal surface of the tar (challenge sire) 
or the shaved back (sensitizarion site). On day 6, pinnal ef'idermal 
specimens were obtained and the population density (cells/ rrun2) of 
la+ Langerhans cells and Thyl+ dendrit ic epidermal cells in each 
experimenr was determined borh by indirect irnmulloperoxidase 
and indi rect immunofluorescence staining, respectively. 
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C o ntact Sen sitivity and C h allenge: Suppression of the Sensi-
tization and E licitation Limbs of tbe CHS Response by 
a·MSH Gro~ps of mice (four per group) were treared on the 
shaved back wah 50 pI of 10- 5 M Q-MSH or diluent on days 1-5. 
One half hour following rhe last treatment, treated or di luent con-
rrol mice were sensitized wirh 25,u1 of 0.5% (0.5 g/ dJ) 2.4-dinitro-
I-fluorobenzene (DNFB) (Sigma Chemical Company. Sr. Louis. 
MO) in a 4 : I acerone:oli\<e oil mix-rure or with 2S,u1 of 100/0 
4~ethoxy-methylene 2-phenyloxazol-S-onc- (oxazalone) (Sigma 
Chemical Company, Sf. Louis, MO) applied to rhe shaved back 
epidermal sire. On day 6. mice were sensitiz.ed again with rhe re-
spective haprellS, DNFH and/ or OX. and resred for five days. On 
day II, ears of treated and comrol mice were measured 2S baseline. 
The cars were challenged with 20)11 o f 0.2% (0.2 gjdl ) DNFB or 
20)11 of 1 % (1 gj dl) ox •• alone. On d.y 12, theear thickness was 
measured a second time. Percent suppression was calculated as: 
% suppression = 
[ 
I-(experimental-negative control) ] 
. . J(dil) . X 100%. positive contro uent -negatIve conrrols 
Tbe degree of ear swelling was determined as described [18]. Elici-
rarion of the CHS response was curied Out similarly except the-
anima ls wc-re treated on the ears on days 1 - 5 with SO pi of 10- 5 M 
a-MSH or propylene glycol and then sensirized on th(' untrea red 
shaved back with eirher DNfB or OX. 
Ad o ptive Transfer of Splenic Sup pressor Cells Groups of 
mice were ropically treated with 10-5 a-MSH or propylene glycol 
for fi ve days On the shaved back. On days Sand 6 rhe m.ice were 
sensitized with DNFB and five d3ys later (days 10 and II ) were 
challenged on the ear to demonstrate the CMS response was im-
pajred. On day 13. spleen cells were taken from created and comrol 
mice and injected intravenously into syngeneic naive recipients. 
Splenocytes from O'-MSH-rreated mice were prepared by reasing 
sph:ens With fo rceps Or WIth a glass rod in HtlSS fol1owed by filter-
ing through :t nylon mesh (T etko. Inc .. Elmsford, NY). The cells 
were then washed three times in HESS and the red blood cells 
(Rae) were lysed in NH .. Cl:Tris buffer. The unfractionared splc.nic 
lymphocytes w ere then layered onto Lympholitc (densiry 1.087) 
(Accurate GhemicaJ Company. Westbury, NY) and centrifuged for 
30 min at 2S"C. The interface containing the lymphocytes were 
then washed TWO addirion:ll rimes to remove any further ce llular 
debris. Spleen cel l suspensions were then injected ultravenously via 
the tail vein of mice at a dose of 1 X 1011 viable cells. Vi3biliry was 
consistently greater than 90% by trypan blue dye exclusion. 
T o determine whether T suppressor or T helper activity was 
induced by applications of (.t'-MSH and/or DNFB, a functional 
adoptive transfer assay was used as described and used by other 
invcstiga.tors l4,21] . Groups of recipient mice were challenged im-
mediately , and 24 h later their ears were measured. Splectl or lymph 
node cells containing sensitized T helper cells (Tit) wOllld induce 
these animals [0 give a positive response to elicitation chalJenge 
with the appropriate hapten applied immediately a.fter adoptive 
transfer. Other recipient animals were sens itized and challenged 
five days later. Recipient animals receiving lymph node or splenic 
cells conra.ining signifi cant T suppressor activity wouJd respond less 
vi~orously than conttol ani.mals. Such animals would functionaHy 
have received T suppressor (T ,) lymphocytes. 
Ado ptive T ransfer o f Draining Lymph N ode E H'ector C e lls 
Inguinal. axillary and btachial lymph nodes were surgically exci.sed 
from a-MSH and control treated/DNFB contact sensitiz.ed mice. 
Single ce ll sllspensions werc prepared. as described in the splenic cell 
preparation. with rbe exception of rhe RilC lysing step. Groups of 
naive mice received at least 1 X 106 viable. draining lymph node 
(DLN) cells intravenously into the tail vein . Groups of mice chen 
were challenged on rhe ears immediatei.y and eat sv.'elling measured 
at 24 h larer or were sensitized and challenged five days later. T 
helper or suppressor acriviry was assessed by the response as noted in 
the section On merhods for adopr.ive transfer of spleen cells. 
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Reconstjtution of CHS Responsiveness After ET AF Admin-
istration E"T AF / IL-l was prepared for in vivo reconstiturion stud-
ies as follows: Murine ET AF was prepared by a modi fication of the 
described method [121. Briefl y, conditioned medium [rom the ke ra-
rinocyre ccllEne PAM 212 was collected and the cell-free superna-
t:t ll( was purified by uhrafilrrarion and Sephadex G- l 00 chromatog-
raph y. Active fractions were pooled and concemrated and 
chroma to graphed on a 41 X 250-mm Synchropak AX 300 ion ex-
change column (Synchrom Inc., Linden, IN). Active frac tions then 
were: pooled on a TSK :;000 column. The active fractiOn!> were 
pooled and concentrated yielding approximately 500 U / ml of 
ETAF/ IL-I activity. 
Groups of mice were treared with 50,tl1 of 10-s M O'-MSH or 
di.luenr on the shaved back for five days. T hi rry minutes after the 
final epiclltaneous [reaemem. mice received 100,tl1 of ETAF or PBS 
diluent administered imradermally or intravenously via the tail 
vein. T hirty minutes later {he mice were sensitized with 0.5% 
DNFB. Twenry-four ho urs later the mice received a second injcc-
6011 ofETAF/ IL-l or PHS intradermally or intravenously, fo llowed 
30 min later by a second application of 0.5% ONES . Five days later 
the mict' were challenged on the ears as described. 
Statistics The statistical significance of differences berween the 
me;!n ear thickness of the experimental conrrol group was calcu-
lated with the Student's r tcst . Mean differences were conside.red 
significant when p was less than 0.05. 
RESULTS 
Effect of Topically Applied a:-MSH on Epidermalla+ Lan~ 
gerhans Cells and Thy l + Dendritic Epidermal Cells A 
10-!o_M concenrration of O'-MSH applied to [he dorsa l surface ear 
skill of mice for nve days produced no signi.ncanr changes in [he 
population density of idemifiable la+ dendriric epidermal cells {pre-
sumably function.ally active antigen presenting Lallgerhans cells} 
(T able'" I) (f = 1.56; P < 0 .12) versus vehicle controls. T o determine 
if topicaJJy appl ied Q-MSH was affecring the phenotypic expression 
of the Thy1.2 di.ffcrc.ntiation marker and causing an alteration of 
these identifiable T hy l+ dendritic ce lls from the epidermis. other 
ct-MSH-treated epidermal sneets and contTol specimens were si -
multaneously srained with Thyl .2 and asialo GM- I membrane 
markers (Table I) [22-33]. In contrast to the la+ Le, {here was a 
slight but. signi ficant 160/0 (r = 2.10; P < 0.05) decrease in Thy 1.2 
mathr expression versus rhe diluent controls (Table I). There was 
no sign.ificant difference in the phenotypic expression of asialo 
GM-I marker (r = 0.406; p> 0.66) (T able I). It should be noted 
th:"l.t the diluent -alone had no effects on b. Thy1 or asialo GM-l 
expression (da ta not shown). W e concluded from these expcrimems 
that t'picutancous application of a-MSH could selectively alter the 
Thy1.2 phenorypic cel l marker c:.xpression, bur nOt asia lo GM-l. 
T his suggests that (l-MSH had no effect on the densiry of the cells 
wi thin the epidermis. 
Suppression of Sensitization CHS Reactivity by QwMSH 
Groups of mice thar were nea ted with Q'-MSH (Fig 1) on th('" dorsal 
skin demonstrated 64% suppression in car thickness in animals 
Table 1. Identi fication of 1.+. T hyI.2+ •• nd Asi.lo GM-I+ 
Phenotypic Marke rs on Ia+ Dendritic Cells and Thy l + I?EC 
Cells/ mm2 ± SEM on Pinnal Epidermis of C57BL/ 6 M.lce 
T reated With cr-MSH or Di luent 
Dose Asi.lo 
irearmenr Applied Site b Thy 1.2 GM-I 
Q-MSH 10 ~ M Ea, 408 ± 19 340 ± IS" 465 ± 18 
Propylene- g ly~ 
e-.ol (diluent) Ea, 446 ± 19 404 ± 14 434 ± 16 
" p < 0.01 compared with diluent (propylene glycol) control aninuk 
D ata reprcscntS thr mean numctLo[ drnsiry (ce[[~/rnmZ) o(identi6ablc: b+. Thy l+. 
and ;asialo GM~ 1 + phenotypic markers from dendritiC epidermal cells from twa com~ 
binc:d expcr;m elln, four mice/ trial ± SEM 
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Figure 1. C HS responsn'eness to DNFB and ox in C57BLj 6 mice treated 
on shaved dorsal epidermis for five davs with 50,t.ll of 10-5 M a-MSH or 
propylenl' glycol. followed by scnsitiz.a'tion by DNfB or ox o n [he [re;ned 
shaved dorsal area . five days I,mr the animals were challenged on the pinnal 
epidermis with either DNFB or OX. Dil uent eat$ wert' significantly thicker 
(p < 0_001) than tre.ated cars in both DNFB and OX treatment groups. The 
treatcd cars were nOt significantly thicker than negativt" control mict" (ch<l.l-
lcnge only) fo r both DNFB and ox approxirnatel y 13% increase in car 
thickness. Data represents ch I!' mean ipcrease in ear thickness from two 
combined experiments- (four mice/ trial ± SEM). 
treated wirh DN FB and 99% depression in ear swelling following 
OX treared vs control mice (I = 2.54; P < 0.05; t = 2.80; P < 0.01, 
rcs.pectively). Negative. control animals did not show any signi.ficant 
differell ce in the ear swelling (cha llenge.d only) and served as an 
indicator for irritant effects of the ONFB hapren. Other negativt" 
control mice challenged only with OX demonstrated similar C HS 
responsiveness as the DNFB negative control mice (i.e_. both nega-
tive control groups dcmonstra ted only 13% increase in ear thick-
ness) after ONFB or OX trearment (data Dor shown). Further, pilot 
experimenrs demonstrated that the dil uem (propylene glycol). 
when applied alone. produced no effects On eithcr the sensitization 
or elicitation limbs of the C HS response (dara nor shown). or the 
density (ce lls/ mm 2) of la+ and T hy l .2+ dendritic cel ls. T he results 
suggest that the epicuraneous application of Cl-MSH can abrogate 
sensicization to (wo differenr antigens/ haptens resul ting in the ab-
sence of an el icitation response at a distal challenge site. 
Sup.pression of the Efferent CHS lnilammatory Response 
After Applicati.on of Q~MSH Elicitation of C HS responsiveness 
was assessed in animals whose ears were trea.ted on days 1 - 5 with 
50,u1 of 1O- s M Q-MSH or propylene glycol. Animals were chen 
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Figure 2. El icitarion of the C HS respo~ to DNFB of C57BL/6 mice 
tte.ted on the dorsal surface of the ear- with 50 JlI of 10- 5 M a-MSH or 
dil uent, and sensitiud on untrc2ted dorsal epidermis. Pos(chaJlenge ea r 
thidUlesS of diluenr was signilicandy greater dun the Q-MSH treated t2.fS 
(p < 0.001). 
s~nsi [ized with DNFB on [he untreated shaved back and challenged 
on d.ay 11 as described above. Twenty-four hours post-ONFB chal-
lenge, [he O'-MSH-trearcd cars demonstrated 61% suppression in 
eor swell ing versus control mice (I = 2.23; P < 0.05) (Fig 2). 
T o determine if [he effects of O'-MSH treatment could be due ro a 
local effect or [0 systemic reactivity. [he following experiments 
were performed. Initial experiments were carried out in which 
C57BL/ 6 micc were treated with a -MSH on the shaved dorsal 
surface for five days followed by sensitization with DNFB on the 
untreated shaved abdomen and challenged on day 11 on the ears as 
was perfonned in tbe earlier experiments. Although mice treated 
with a-MSH on the back and DN FB on the abdomen responded 
less vigorously than controls (column Band C , Fig 3), tbe difference 
was nor significant statistically (t = -1.60; p > 0.87). It would ap-
pear. at least from these dara. that topically applied o:-MSH . at the 
dose applied under these specific experimental condi tions in vivo. 
may act local ly. Subsequent experiments suggested a-MSH had 
systemic/splenic effects as well . 
Effect of Splenic Suppressor and Helper CeU Activity After 
a.MSH Topical Treatment on DNFB/ CHS Responsiveness 
To determine if a-MSH could induce suppression via splenic sup-
pressor cell activity. passive cell tn.nsfer studies were performed. 
Results are depicted in Figure 4. T here was a significant percent 
suppress ion (45%; t = 2.35, P < 0.05) in car swelling in immuno-
logically naive mice, which received splenocytes from o -MSH/ 
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Figure 3. Local dtect of cpicuuneousl y appl ied a -MSH on C HS rl"'spon-
Slveness to DNFB. Groups or mice" werl"' treared with So,ul or 10- S Q'-MSH 
or propylene glycol on the shaved dorsaJ surface fo r five days. The mice." were 
then sensitized with 0.5% DNFB on thl" tre,tled back (bars A anJ B) or 
abdomen (bars C atlJ D). five days later the can were measured and chaJ-
lengc.d ..... ith 0.2% DNFB. Micl" tftlted with I)-MSH (bar A) or diluent (bar 
B) and then sensitized on {hI" treated dor.ul epidermis demonstrated signifi-
cam decre:.lse in e:.lr thickness versus thl" diluent controls (bor B) (p < a.OO l ). 
However. mice treated with Q-MSH or prop},lenl" glycol (bars C anJ D) on 
the dorsal epidl"rmis :.Ind sensitit.ed on the untreated :.Ibdomen wl"re not 
signinc:lntly dHfe.renr (p > O.S7). Negaci ve controls (p.mel E) received chal-
lenge dose of DNFB o nly. 
DNFB (treatment ~-MSH-ccll transfer sple~n)- treated mice that 
were then sensitized and challenged wi rh DNFB. O'-MSH or an-
other as yet to be identified biomolecule may be inducing the ob-
se rved systemic suppressor activity f34]. 
R ole of DLN Cells in CHS Responsiveness Mter a·MSH 
Treatment In the above experiments. we noted suppression fol-
lowing passive transfer of splenocytes [0 naive mice after topical 
~-M.SH and DNF.13 sensitization treatment. Separate experiments 
were designed to examine whether donor lymph node effector cel ls 
were capable of sensitizing naive mjc~ after topical Q-MSH treat-
ment and DNFB allergen sensitization. Donor mice were trea ted 
with 10-' M ",-MSH or propylene glycol for five days followed by 
DNFB sensitization and challenged five days later. Draining lymph 
node cells were isolated from MSH~rreated mice and control mice. 
These cells were injected intravenously on 1 X J06 viable cells via 
the tail vein into naive recipients . Groups of mice were either imme-
diately challenged and ears measured 24 h later or immediately 
sensi tized and challenged five days later. The extent of ear swelling 
was measured 24 h posrchallenge (Fig 4). O Uf results demonstrate 
that there was no significant difference in the elicitation of CH S 
response in recipient mice receiving drai ning lymph node cells from 
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Figure " . Adoptive transfer of spJenocytes and draining lymph node cells 
from topIcally treated a-MSH or diluent treated DNFB sensitized mice to 
immunologically naive recipient mice. Croups of recipient mice were either 
immediately cball enged or sensitized with DNFB and effector (Th-hclper) 
or suppressor (T,) cellacti"jty assessed at either 24 h or five days later after a 
challenge dose of 0.2% DN FB to pmnal epidermis. Adoprive transfer of 
spleen cells (T J from a-MSH/ DNFB sensitized donors intO naive recipients 
resulted ill a signi ficant amount of SlIpprcssor .activit)· (p < 0.05) in treated 
anima ls versus propylene glycol control mice (treatmen t dil / a-MSH -cell 
transfer spleen) . Splenocytes from a-MSH treated 2nd sensitized mice trans-
ferred into nOlive mice followed by immediOlte challenge resulted in no 
discernible changes ill responsiveness between a-MSH 2nd diluent controls. 
In sep:l.fOIte experiments we observed that the cOlpacity to dicit chI:' C HS 
response to DNFB using DLN ce lls was not significantl y different ill mice 
challenged i.mmediately or sensitized 2nd challenged fi ve d2YS l:ner. Data 
shown are resul t~ of tv.'O experiments (four mice/trial ± SEM) with splenic 
cells and two separate experiments on DLN cells. 
figure S. Suppression of C HS respon· 
siveness in a-MSH topical ly m'2ted mice 
could be reconstituted with either intra-
dermal or intravenous injections of ken-
tinocyte derived ETAf/ IL- t. Groups of 
mice topically treated with 50,tll of 
to- 5 M (l'-MSH or diluent for "ve d.ays. 
Thirty minutes aftcr treatment, groups of 
mice received 0.1 ml of ETAF (500 
U/ ml) either intradcrmally into the tOpi-
cally treated s.ite or intr.lvenous.ly via the 
tail vein. Thirty minutcs after ET AF) U .... 
I administration. mice were sensirized to 
25,t11 of 0.5% DNFB on the treated 
shaved dorsal epidermis. The ETAF/ IL-l 
sensitization procedure was repeated 
again on d2Y 6. Five Ibys \atcr . on day 11 , 
the e:lfS were measured 2nd challenged 
with 20 J.d 0[0.2% DNFB. Twcnty~four 
hours later the ears werc measured again. 
Mice treated with a-MSH followed by 
ETAF j tL-l tteatment tesulted in recon-
stitution of the CHS response with values 
simii2r to th2t obtained with diluent con-
trois. 
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either tre.ated or diluent control mice. This suggests, .albeit by no 
means absolute. that l.pplications of DNFB after trc:arment of the 
sk in with O"-MSH resulted in .an immuno logicall y null event afte r 
passive tran.sfer of draining lymph node ce lls. However, the above 
experiments suggest that Q-MSH may acci vate both local and 
s~lenj c suppressor ac tivities possibly by several different mccha-
Illsms. 
Reconstitution of CHS Response Mter Administration of 
ET AF / lL-l to a-MSH-Treated Mice To determine if suppres-
sion of C H S responsiveness was related to aher.arions in IT AF / 1L-l 
bio.ac:tivity , reconstitution experiments were perfo rmed. a-MSH -
tre.ared mice received ei ther intr.adermal or intravenous injections of 
ETAf / IL-l before sensitiz.ation with DNFB. The results are shown 
in Fig ure 5. Mice treated wi th Q-MSH followed by intradermal o r 
intravenous injections of ETAF demonstr.ate significantl y greater 
increase in thickness versus mice treated with a -MSH/ DNFB only 
(r = 2.73,F < 0.01 ; r = 2.92,p < 0.01 , respectively) . W e were able 
to concl ude from th.is experiment that intradermal and inrnveno us 
systemic admi nisrr.ati on of the ETAF/ IL-l molecule could restore 
C H S responsivencss to DNFB inC57BL/6 mice. Mice treated topi-
cally with propylene glycol followed by injections of ETAF reacted 
less vigorously to DNFB sensitu.ation and chall enge than the di-
luen t control. N o further experimentS were undertaken at this point 
to determine if this was related to the dose or o ther variables. 
D ISCUSSION 
Alp h.a- melanocyte srimuhting hormone (a-MSH) is the best 
kno w n .and classic melanotropic agent. While origin.all y described 
in the pars intcrmedia of the pituitary gland , a-MSH can be found in 
othcr organs of the body including the sk.i n p}. Further. it is known 
thar immune cel ls from the spleen and thymus can se rve as a.n extra 
pituitary source for precursors of a-MSH, i.e., P-LPH and AC TH, 
that in turn can modulate immune responsiveness locally or syS[em-
icaHy without pi ruitary influences J35]' Preliminary d.at.a from o ur 
laboratory including immune ioc.aJizarion by EM and immunoblots 
on PA GE .. separared proteins suggest that the Thy I + dendritic epi-
dermal cel l. a cell of T-celllineagc:.. may produce Q-MSH o r o ther 
MSH peptides or promolecules th.at have an immunomodul.atory 
effect on the skin (36}. MSH is derived from.a much larger peptide, 
proopiomelanocortin (POMC). 
In the last four yea.rs a-MSH h as been found to be .a potent 
inhibitor of fL-I bioactivity f4 - 6J. a-MSH in nanogram quantities 
can apparently block mOlny activit ies of tht. l.L--l mo\ecule. Other 
investi gators have documemed both in vitro and in vivo the inhibit-
ing capacity of a-MSH o n IL- t immune activities f4 - 6]' A1though 
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Q-MSH can "down regulate" generation of acute phase reacC'ant 
proteins from the liver, thymocyte prohfer.uion. and induction of 
neutropenia. there has been a pauciry of studies on the role of topi-
cally applied O'-MSH regarding its effect o n the epidermal immune 
system. versus systemic Lntr"venous administration of lr-MSH. 
In this study, we have shown that epicuuneous application of the 
molecule Q-MSH on the epidermis can suppress both the sensitiza-
tion (induction) a.nd elicitation limbs of the cuta.neous immune re-
sponse. Dawson and co-workers [37] have shown that Q-MSH r:ap-
idly penctta.rcs the ep idermis of murine and human skin. The effect 
of Q-MSH appears to demonstrau· both local as well as systemic 
react ivity. However. the exact biochemical and immuno logical 
mechanisms for these observations remain unknown. 
In the current studies. not only could we suppress the sensitiz.a-
tion and elicitation limbs of the cut:meous immune response, but we 
could reconstitute the in vivo activity after injections ofETAF / IL-t 
both illtradermally as well as intravenously. Although injections of 
ETAF intradermally and intravenowly did not demonstrate 100% 
n:constitution ofCHS to control (diJuent) levels. they were signifi-
candy greater than the a -MSH treaunent groups. It is quite possible 
that the dosage and kinetics of ET AF / IL-l injected intnvenowly 
and/or intradennally may have different bioactivities that could 
explain our observed discrepancies concerning absence of t 00% 
reconstitution of the C HS response. Further. small contaminants to 
ETAF/ IL-l (i.e., IL-6 and GM-CSF) mighr have some effect. Pre-
liminary experiments suggest this is not the case (daca nor shown). 
W e have no explanations for the apparent suppressive effects of 
intravenous doses of ETAF (Fig 5). 
The fact that mice were sensitized rwice after Q-MSH treatment 
which still resulted in cutaneous immune suppression suggests thar 
several factors may be involved in rhe observed phenomena. 1£ 
should be noted that Q-MSH has a short half tife when injected 
intravenously. Topical treatment of Q-MSH may al ter a variery of 
epidermal cel l fUllctions and/or secretion of Iymphokines. cyto-
kines , or other epidermal biomolecules (i.e .• prosraglandins.leuko-
trienes, ACTH. or epidennal growth factor), which may prove to 
be. necessary for contact sensitization {34}. Our studies are at least 
consistent with some of the observations of Cannon et al !51, who 
documented in 1986 that Q'-MSH could inhibit lL- l -dependent 
thymocyte stimulation. Caution is necessary in comparing our re-
sults and those of Cannon because the experimental conditions and 
org:an syscems used were different. 
Daynes et al 161 demonstrated in 1987 rhat intravcnous adminis-
tration of either Q-MSH or a syn thetic analogue was unable to 
abrogate fl.! to stimulate production of PG~ or PHA stimulation 
of murine thymocytes. W e also used a synthetic an:alog of lr-MSH 
(Nle.D-Phe a -MSH) and found no al terations in function of the 
cutaneous immune response or epidermal immune cells with th is 
analogue (data nor shown). This observed discrr-pancy may be due to 
sevenl mechanisms working together with ETAF/ IL- l 2cting on 
various epidermal cdls. which may lead to alteratioll5 in the contact 
hypersensitivity response. For example, ETAF and a novel 11.--1 
termed K- IL-ll1 1.381 comprise at least three peptides, IL-1Q and 
lL-1P, all of which arc produced by epidermal cells and may sepa-
rately , synergistically, or addi rive ly al ter C HS reactivity, depending 
on the route of Q-MSH administration. However, in other studies 
we have investigated [he agonist/antagonist effects of Q-MSH and 
ETAF in more det ... il. W e observed that the inhibitory effects. at 
least in the melanocyte system, could not be 2ttributed to simple 
receptor competition. Moreover the inhibi tory effects of ET AF 
could nor he reprod uced by [L-l<r, 1L-1P, CSF-GM, or 1L-6 alone or 
in any combin:a.tion t411. Sufficient quantities of KlL-1 are not avail-
able for study. Although we have not completed identical experi-
ments on Langerhalls cells or lymphocytes. we are devoting signifi-
cant amounts of our attention at this time to elucidating the 
agonist/antagonist effects of ET AF a.nd MSH. 
W hen C57BL/6 mice were topically treated with Q-MSH, there 
was no loss ofidentifi.a.ble dendritic b+ Langerhanscells. However, 
there waS a 16% decrease in Thy1.2 markers on Thyl+ dendritic 
epidermal cells. although the number of asialo GM-l muk.ers, the 
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marker found predominamly 0 11 N-Iymphocytes (NK cells), re-
mained constant. Q'-MSH may have many cffects on phenotypic 
marker expression on some subpopulations of T hy l+ cells by per-
haps down regulating Thyl.2 marker expression itself or serving as 
a transducer signal to another biologically relevant molecule that is 
necessary for CH S reactivity. From concurrent srudjes, we would 
!.ike to suggest that the Thyt+ DEC may serve as a reservoir for a 
variety of proopiomelanocortin neuropeptides (i .e., Q-MSH, P-li-
parropin. ACTH) which in turn Gan down r~gul:ate the epidermal 
immune SYSTem [36]. This may be of particular importance in light 
of the fac t That the exact function of the Thy1.2 difFcrentiation 
marker remains an immunologic enigma \39]. The Thy l .2 marker 
may function in trafficking the Thyl+ DEC to the epidermis, 
which in rurn may seNe as an extra thymic environment for this 
particular dendritic cell. In vitro epidermal lymphocyte experi-
ments (ELR) are currently underw·ay with enriched FACS sorted 
epidermal cell s in the presence of Q-MSH and ocher neuropepr.ides 
to begin to ascernin information on these questions using a mOTe 
precise experimental system. 
The results of our data have possible significance for understand-
ing the regulation of epidermal immune functions. W e have identi-
fi ed by immunfluorescence a-MSH in the skin (data not shown), as 
well as p-lipotropin (36). Recent preliminary work from our lab 
with appropriate eDNA probes confi rmed the presence of mRNA 
for POMC in epiderm3-1 cells 140). W e suggcst that the release of 
Q'-MSH from the appropriate cel l may function as a biological mod-
ifier [0 both increase melanocyre function as well as to modulate the 
intensity of an immune/ inflammatory activity . This :a nd the results 
of other work suggest that biological modifi ers like Q-MSH may be 
usefuJ rherapeutic:dly in the care of patienrs with many or all rypes 
of epidermal inflammation. 
The tmthors gratrJidly tlckrroul/edge th~ tm;sranc{! oj Ms. Joan C ri.Ms if! prt'paratiorl 
.if the marlllsrript. 
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